{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lillie PJ"],"funding":["Medical Research Council","Wellcome Trust"],"pagination":["19-25"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3369564"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["55(1)"],"pubmed_abstract":["Background
The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers.Methods
Volunteers with no measurable serum antibodies to influenza A/Wisconsin/67/2005 received either a single vaccination with MVA-NP+M1 or no vaccination. T-cell responses to the vaccine antigens were measured at enrollment and again prior to virus challenge. All volunteers underwent intranasal admi"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans."],"pmcid":["PMC3369564"],"funding_grant_id":["095540","G1001046","G0600520","081865","090532"],"pubmed_authors":["Peng Y","Dong T","Lambe T","Sheehy SH","Hill AV","Blais ME","Gilbert A","Oxford J","Gilbert SC","Spencer AJ","Hamill M","Duncan CJ","Havelock T","Powell TJ","Lillie PJ","Williams RL","Mullarkey C","Berthoud TK","Faust SN"],"additional_accession":[]},"is_claimable":false,"name":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.","description":"Background
The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers.Methods
Volunteers with no measurable serum antibodies to influenza A/Wisconsin/67/2005 received either a single vaccination with MVA-NP+M1 or no vaccination. T-cell responses to the vaccine antigens were measured at enrollment and again prior to virus challenge. All volunteers underwent intranasal admi","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Jul","modification":"2026-05-04T20:53:30.618Z","creation":"2019-03-27T00:54:15Z"},"accession":"S-EPMC3369564","cross_references":{"pubmed":["22441650"],"doi":["10.1093/cid/cis327"]}}